SILDENAFIL CITRATE
AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION
CADISTA PHARMAC
Drug class
Pulmonary Antihypertensive Agents, cGMP pathway
Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling. Read more about Pulmonary Antihypertensive Agents, cGMP pathway
84 drugs in this class 48 manufacturers
Drugs in Pulmonary Antihypertensive Agents, cGMP pathway
SILDENAFIL CITRATE
AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION
GSMS, INC.
RIOCIGUAT
PULMONARY ANTIHYPERTENSIVE AGENTS, CGMP PATHWAY · PULMONARY ARTERIAL HYPERTENSION ·+1
ZYDUS PHARMACEU
Filter & compare in the drug finder →
Opens the drug finder with Pulmonary Antihypertensive Agents, cGMP pathway preselected. Add indication or manufacturer filters there.
Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling.
They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP.
By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4).
-
nih.gov
Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling
-
nih.gov
Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP By facilitating smooth muscle relaxatio...
-
fda.gov
They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP
-
nv.gov
They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP
-
fda.gov
By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)
-
fda.gov
By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)
-
frontiersin.org
By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.